Unplug from tubing. Unlock real freedom.
Zero Tubes. Everyday Confidence. Total Freedom.
Omnipod 5 proactively helps to correct highs and protect from lows–simplifying your diabetes management. 1, 2 No multiple daily injections or [routine] finger prick testing.‡
“Being able to have the Pod on and knowing it’s there for 3 days gives me a sense of freedom.”
Dan N
You didn’t sign up to manage tubing. Omnipod 5 gives you the automation you expect - without being tethered by tubes.
How it works
Every five minutes the glucose Sensor reports glucose levels to the Pod which automatically adjusts your insulin.
- When glucose levels are dropping, insulin delivery automatically decreases or pauses.
- When glucose levels are rising, insulin delivery automatically increases.
†The Pod has an IP28 rating for up to 7.6 meters (25 feet) for 60 minutes. The Controller is not waterproof.
Still stuck with tubing? You deserve better.
No Tubes. No Tangling. Just a Smarter Way to Manage Diabetes.
Next up...
Experience freedom with Pod Therapy
The free Pod Experience Kit* , which includes a non-functioning Pod, is designed to help you understand what it feels like to wear the tubeless Pod and get a sense of how discreet it can be. Find the area that works best for you, the Pod can be worn almost anywhere you would give yourself an injection, and discover the difference for yourself.
Try it for yourself
Nothing beats firsthand experience. The free Pod Experience Kit* (PEK) contains a needle-free nonfunctioning demo Pod for you to wear. It also includes a quick-start guide providing you with more information about the Omnipod® System.
Talk to an Omnipod® Specialist
Still have more questions about the Omnipod® System? Enter your information below and one of our Omnipod® Specialists will call you in 24-48 hours for a one-to-one chat. Or you can call us direct at 0800 011 6132* (option 4) or +44 20 3887 1709 (option 4) if calling from abroad.
‡Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
†The Pod has an IP28 rating for up to 25 feet/7.6 meters for 60 minutes. The Controller is not waterproof.
§Sensor sold separately and requires a separate prescription. Compatible sensors vary by country.
*The demo Pod is a needle-free, non-functioning Pod.
1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in hyperglycaemic range (>10.0 mmol/L or >180mg/dL) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 28.9% vs. 22.8%; 44.8% vs 29.7%, P<0.0001, respectively. Mean time in hypoglycaemic range in adults/adolescents and children (<3.9 mmol/L or <70 mg/dL) as measured by CGM: ST = 1.89%, 3-mo Omnipod 5 = 1.32%, P<0.0001; ST = 2.21%, 3-mo Omnipod 5 = 1.78%, P<0.0456 respectively.
2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-day standard therapy (ST) phase followed by a 3-month AID phase with Omnipod 5 system. Mean time in hyperglycaemic range (>10.0 mmol/L or >180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 39.4% vs. 29.5%, P<0.0001, respectively. Mean time in hypoglycaemic range (<3.9 mmol/L or <70 mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 3.43% vs. 2.46%, P=0.0204."
Risk Statement
The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin.
The Omnipod 5 System is intended to operate as an automated insulin delivery system when used with compatible Continuous Glucose Monitors (CGM). When in automated mode, the Omnipod 5 system is designed to assist people with type 1 diabetes in achieving glycaemic targets set by their healthcare providers. It is intended to modulate (increase, decrease or pause) insulin delivery to operate within predefined threshold values using current and predicted CGM values to maintain blood glucose at variable target glucose levels, thereby reducing glucose variability. This reduction in variability is intended to lead to a reduction in the frequency, severity, and duration of both hyperglycaemia and hypoglycaemia.
The Omnipod 5 System can also operate in a manual mode that delivers insulin at set or manually adjusted rates.
The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with U100 rapid acting insulin.
WARNING: SmartAdjust™ technology should NOT be used by anyone under the age of 2 years old. SmartAdjust™ technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population. The Omnipod® 5 System is NOT recommended for people who are unable to monitor glucose as recommended by their healthcare provider, are unable to maintain contact with their healthcare provider, are unable to use the Omnipod® 5 System according to instructions, are taking hydroxyurea and using a Dexcom Sensor as it could lead to falsely elevated CGM values and result in over-delivery of insulin that can lead to severe hypoglycaemia, and do NOT have adequate hearing and/or vision to allow recognition of all functions of the Omnipod® 5 System, including alerts, alarms, and reminders. Device components including the Pod, CGM transmitter, and CGM sensor must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment. In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to MRI, CT, or diathermy treatment can damage the components. Visit https://www.omnipod.com/en-gb/safety for additional important safety information.
WARNING: DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.